FI930608L - Nya farmaceutiska formulationer av 5-(2-klor-1-hydroxietyl)-4-metyltiazol - Google Patents

Nya farmaceutiska formulationer av 5-(2-klor-1-hydroxietyl)-4-metyltiazol Download PDF

Info

Publication number
FI930608L
FI930608L FI930608A FI930608A FI930608L FI 930608 L FI930608 L FI 930608L FI 930608 A FI930608 A FI 930608A FI 930608 A FI930608 A FI 930608A FI 930608 L FI930608 L FI 930608L
Authority
FI
Finland
Prior art keywords
hydroxietyl
formulationer
farmaceutiska
nya
methylthiazole
Prior art date
Application number
FI930608A
Other languages
English (en)
Finnish (fi)
Other versions
FI930608A7 (fi
FI930608A0 (fi
Inventor
Bernard Robin Boar
Alan John Cross
Alfred Richard Green
Curt-Eric Hagberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of FI930608A7 publication Critical patent/FI930608A7/fi
Publication of FI930608A0 publication Critical patent/FI930608A0/fi
Publication of FI930608L publication Critical patent/FI930608L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
FI930608A 1990-08-15 1991-08-07 Nya farmaceutiska formulationer av 5-(2-klor-1-hydroxietyl)-4-metyltiazol FI930608L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9002659A SE9002659D0 (sv) 1990-08-15 1990-08-15 New pharmaceutical formulations
PCT/SE1991/000522 WO1992003134A1 (en) 1990-08-15 1991-08-07 New pharmaceutical formulations of 5-(2-chloro-1-hydroxyethyl)-4-methylthiazole

Publications (3)

Publication Number Publication Date
FI930608A7 FI930608A7 (fi) 1993-02-11
FI930608A0 FI930608A0 (fi) 1993-02-11
FI930608L true FI930608L (fi) 1993-02-11

Family

ID=20380161

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930608A FI930608L (fi) 1990-08-15 1991-08-07 Nya farmaceutiska formulationer av 5-(2-klor-1-hydroxietyl)-4-metyltiazol

Country Status (26)

Country Link
US (1) US5385921A (is)
EP (1) EP0619734B1 (is)
JP (1) JP3094077B2 (is)
AT (1) ATE164066T1 (is)
AU (1) AU657490B2 (is)
BG (1) BG97446A (is)
CA (1) CA2088775A1 (is)
CZ (1) CZ279586B6 (is)
DE (1) DE69129126T2 (is)
DK (1) DK0619734T3 (is)
ES (1) ES2114891T3 (is)
FI (1) FI930608L (is)
HU (1) HUT65821A (is)
IE (1) IE912818A1 (is)
IL (1) IL99169A (is)
IS (1) IS3743A7 (is)
LT (1) LT3978B (is)
LV (1) LV10921B (is)
NO (1) NO303447B1 (is)
NZ (1) NZ239329A (is)
PT (1) PT98688B (is)
RO (1) RO112994B1 (is)
RU (1) RU2093155C1 (is)
SE (1) SE9002659D0 (is)
SK (1) SK8793A3 (is)
WO (1) WO1992003134A1 (is)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901658D0 (sv) * 1999-05-06 1999-05-06 Astra Ab New formulation
SE9904177D0 (sv) * 1999-11-18 1999-11-18 Astra Ab Novel compounds
WO2002083863A2 (en) 2001-04-17 2002-10-24 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
CN103772313B (zh) * 2014-01-02 2015-10-14 郑桂富 一种4-甲基-5-(2-羟乙基)噻唑的合成方法
CN112262814A (zh) * 2020-10-26 2021-01-26 宜宾学院 油樟叶渣发酵床养鸡方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2825966A1 (de) * 1978-06-14 1980-01-03 Basf Ag Saures galvanisches nickelbad, das sulfobetaine als glanz- und einebnungsmittel enthaelt
GB8600783D0 (en) * 1986-01-14 1986-02-19 Merck Sharp & Dohme N-methyl-d-aspartate receptor antagonists

Also Published As

Publication number Publication date
EP0619734A1 (en) 1994-10-19
BG97446A (bg) 1994-03-24
PT98688A (pt) 1992-07-31
NO930452L (no) 1993-02-09
NO303447B1 (no) 1998-07-13
JP3094077B2 (ja) 2000-10-03
FI930608A7 (fi) 1993-02-11
IL99169A0 (en) 1992-07-15
IL99169A (en) 1995-10-31
CZ279586B6 (cs) 1995-05-17
RO112994B1 (ro) 1998-03-30
EP0619734B1 (en) 1998-03-18
AU8409291A (en) 1992-03-17
SK8793A3 (en) 1993-07-07
PT98688B (pt) 1999-01-29
NO930452D0 (no) 1993-02-09
LT3978B (en) 1996-06-25
IS3743A7 (is) 1992-02-16
LTIP1714A (en) 1995-09-25
DE69129126D1 (de) 1998-04-23
AU657490B2 (en) 1995-03-16
IE912818A1 (en) 1992-02-26
CA2088775A1 (en) 1992-02-16
CZ16693A3 (en) 1994-02-16
RU2093155C1 (ru) 1997-10-20
HUT65821A (en) 1994-07-28
NZ239329A (en) 1994-11-25
DE69129126T2 (de) 1998-07-23
DK0619734T3 (da) 1998-10-05
FI930608A0 (fi) 1993-02-11
US5385921A (en) 1995-01-31
LV10921B (en) 1996-08-20
SE9002659D0 (sv) 1990-08-15
ATE164066T1 (de) 1998-04-15
JPH06500097A (ja) 1994-01-06
ES2114891T3 (es) 1998-06-16
HU9300388D0 (en) 1993-04-28
WO1992003134A1 (en) 1992-03-05
LV10921A (lv) 1995-12-20

Similar Documents

Publication Publication Date Title
FI910228A7 (fi) Indolilla substituoidut viisijäseniset heteroaromaattiset yhdisteet
FI930658L (fi) Oligonukleotider foer modulering av effekten av cytomegalovirusinfektioner
FI930381A0 (fi) Nya vaermestabila pullulanaser
FI932909L (fi) Foergrenade alkylaminoderivat av tiazol, foerfaranden foer framstaellning av dessa och farmaceutiska kompositioner innehaollande dessa
FI923575A7 (fi) Foerfarande foer framstaellning av nya 1-acylpiperidinfoereningar
FI915825L (fi) Heterocykliska foereningar.
FI910503A7 (fi) Nya heterocykliska derivat.
FI930199A7 (fi) Nya substituerade tiazolyl- och substituerade pyridinylderivat
FI930552L (fi) Nytt foerfarande foer framstaellning av nukleotider
FI930198A0 (fi) Nya oxazolylderivat
FI910750A7 (fi) Heterocykliska foereningar.
FI914947A0 (fi) Foerbaettrad expression av polypeptider.
FI920121L (fi) Foerfarande foer framstaellning av heterocykliska hydroxylaminer.
FI932552L (fi) Foerfarande foer framstaellning av en fast enhet doseringsform foer reglerad utloesningen
FI912220A7 (fi) Heterocykliska foereningar.
FI914910L (fi) Heterocykliska foereningar.
FI924746A0 (fi) Kohydrolysfoerfarande foer framstaellning av nya extrakt fraon jaest- och icke-jaestproteiner
FI913817A0 (fi) Nya utfoeringsformer av den huvudsakliga hiv-neutraliserande determinanten.
FI913888L (fi) Nya farmaceutiska sammansaettningar och foerfarande foer framstaellning av desamma.
FI923965L (fi) Heterocykliska steroidfoereningar
FI931630L (fi) Nya proteaser
FI930034A0 (fi) Foerfarande foer framstaellning av avlaongt foeremaol
FI911351A0 (fi) Nya 8-sulfamylmetylen-2 -aminotetraliner.
FI911442A7 (fi) Foerfarande foer framstaellning av nya sulfonyl-b-d-tioxylosider.
FI913607L (fi) Nya mikroorganismer och avaendning av dessa foer tillverkning av charkuterivaror.

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: ASTRA AKTIEBOLAG